Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes

Proteins: Structure, Function and Genetics

Volumn 43, Issue 4, 2001, Pages 455-464

  Mahalingam, Bhuvaneshwari ^a   Louis, John M ^b   Hung, Jason ^b   Harrison, Robert W ^a   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Aspartic protease; Conserved water; Crystallography; Inhibitors; Structural changes

Indexed keywords

DIMER; MUTANT PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; UREA; WATER;

ANTIBIOTIC RESISTANCE; ARTICLE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; PRIORITY JOURNAL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VIRUS MUTANT;

AMINO ACID SUBSTITUTION; BINDING SITES; CATALYSIS; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, MICROBIAL; ENZYME STABILITY; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035370444     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.1057     Document Type: Article

References (31)

1. Shafer RW, Stevenson D, Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 1999;27:348-352.
2. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000;14:1203-1210.
3. Vondrasek J, van Buskirk CP, Wlodawer A. Database of three-dimensional structures of HIV proteinases. Nature Struct Biol 1997;4:8.
4. Mahalingam B, Louis JM, Reed CC, Adomat JM, Krouse J, Wang YF, Harrison RW, Weber IT. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur J Biochem 1999;263: 238-245.
5. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5: 129-142.
6. Tessmer U, Krausslich HG. Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. J Virol 1998;72:3459-3463.
7. Louis JM, Clore GM, Gronenborn AM. Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nature Struct Biol 1999;6:868-875.
8. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, Swanstrom R. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994;68: 8017-8027.
9. Misumi S, Kudo A, Azuma R, Tomonaga M, Furuishi K, Shoji S. The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease. Biochem Biophys Res Commun 1997;241:275-280.
10. Accola MA, Hoglund S, Gottlinger HG. A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J Virol 1998;72:2072-2078.
11. Xie D, Gulnik S, Gustchina E, Yu B, Shao W, Qoronfleh W, Nathan A, Erickson JW. Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH. Protein Sci 1999;8:1702-1707.
12. Louis JM, Wondrak EM, Copeland TD, Smith CA, Mora PT, Oroszlan S. Chemical synthesis and expression of the HIV-1 protease gene in E. coli. Biochem Biophys Res Commun 1989;159: 87-94.
13. Wondrak EM, Louis JM. Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 1996;35:12957-12962.
14. Otwinowski Z, Minor W. Processing of X-ray diffraction data in oscillation mode. Methods Enzymol 1997;276:307-326.
15. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr D Biol Crystallogr 1994;D50:157-163.
16. Brunger AT. X-PLOR version 3.1: a system for X-ray crystallography and NMR. New Have, CT: Yale University Press; 1992.
17. Jones TA. A graphics model building and refinement system for macromolecules. J Appl Crystallogr 1978;11:268-272.
18. Cohen GE, ALIGN: a program to superimpose protein coordinates, accounting for insertions and deletions. J Appl Crystallogr 1997; 30:1160-1161.
19. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, Hutchison CA III. Complete mutagenesis of the HIV-1 protease. Nature 1989;340:397-400.
20. Weber IT, Wu J, Adomat J, Harrison RW, Kimmel AR, Wondrak EM, Louis JM. Crystallographic analysis of human immunodeficiency virus 1 protease with an analogue of the conserved CA-p2 substrate-interactions with frequently occurring glutamic acid residue at P2′ position of substrates. Eur J Biochem 1997;249:523-530.
21. Rose JR, Babe LM, Craik CS. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol 1995;69:2751-2758.
22. Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996;93:13-20.
23. Wu J, Adomat JM, Ridky TW, Louis JM, Leis J, Harrison RW, Weber IT. Structural basis for specificity of retroviral proteases. Biochemistry 1998;37:4518-4526.
24. Lin YC, Beck Z, Lee T, Le VD, Morris GM, Olson AJ, Wong CH, Elder JH. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J Virol 2000;74:4710-4720.
25. Kervinen J, Lubkowski J, Zdanov A, Bhatt D, Dunn BM, Hui KY, Powell DJ, Kay J, Wlodawer A, Gustchina A. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV. Protein Sci 1998;7:2314-2323.
26. Louis JM, Smith CA, Wondrak EM, Mora PT, Oroszlan S. Substitution mutations of the highly conserved arginine 87 of HIV-1 protease result in loss of proteolytic activity. Biochem Biophys Res Commun 1989;164:30-38.
27. Wlodawer A, Gustchina A. Structural and biochemical studies of retroviral proteases. Biochim Biophys Acta 2000;1477:16-34.
28. Tozser J, Gustchina A, Weber IT, Blaha I, Wondrak EM, Oroszlan S. Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett 1991;279:356-360.
29. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999;73:3744-3752.
30. Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR. Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. Biochemistry 1998;37:2105-2110.
31. Rose RB, Rose JR, Salto R, Craik CS, Stroud RM. Structure of the protease from simian immunodeficiency virus: complex with an irreversible nonpeptide inhibitor. Biochemistry. 1993;32:12498-12507.